[go: up one dir, main page]

HK1116779A1 - 作為選擇性hm74a激動劑的黃嘌呤衍生物 - Google Patents

作為選擇性hm74a激動劑的黃嘌呤衍生物 Download PDF

Info

Publication number
HK1116779A1
HK1116779A1 HK08107505.5A HK08107505A HK1116779A1 HK 1116779 A1 HK1116779 A1 HK 1116779A1 HK 08107505 A HK08107505 A HK 08107505A HK 1116779 A1 HK1116779 A1 HK 1116779A1
Authority
HK
Hong Kong
Prior art keywords
compound according
treatment
dyslipidaemia
compound
pharmaceutically acceptable
Prior art date
Application number
HK08107505.5A
Other languages
German (de)
English (en)
French (fr)
Other versions
HK1116779B (zh
Inventor
Richard Jonathan Daniel Hatley
Andrew Mcmurtrie Mason
Ivan Leo Pinto
Original Assignee
Glaxosmithkline Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0516464A external-priority patent/GB0516464D0/en
Priority claimed from GB0607736A external-priority patent/GB0607736D0/en
Priority claimed from GB0614569A external-priority patent/GB0614569D0/en
Application filed by Glaxosmithkline Llc filed Critical Glaxosmithkline Llc
Publication of HK1116779A1 publication Critical patent/HK1116779A1/zh
Publication of HK1116779B publication Critical patent/HK1116779B/zh

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • C07D473/02Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/48Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/08Vasodilators for multiple indications
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • C07D473/02Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Nutrition Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK08107505.5A 2005-08-10 2006-08-08 作為選擇性hm74a激動劑的黃嘌呤衍生物 HK1116779B (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GB0516464A GB0516464D0 (en) 2005-08-10 2005-08-10 Novel compounds
GB0516464.5 2005-08-10
GB0607736.6 2006-04-19
GB0607736A GB0607736D0 (en) 2006-04-19 2006-04-19 Novel compounds
GB0614569A GB0614569D0 (en) 2006-07-21 2006-07-21 Novel compounds
GB0614569.2 2006-07-21
PCT/EP2006/007865 WO2007017261A1 (en) 2005-08-10 2006-08-08 Xanthine derivatives as selective hm74a agonists

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
HK11100453.7A Division HK1146279A (zh) 2005-08-10 2008-07-08 作為選擇性hm74a激動劑的黃嘌呤衍生物

Related Child Applications (1)

Application Number Title Priority Date Filing Date
HK11100453.7A Addition HK1146279A (zh) 2005-08-10 2008-07-08 作為選擇性hm74a激動劑的黃嘌呤衍生物

Publications (2)

Publication Number Publication Date
HK1116779A1 true HK1116779A1 (zh) 2009-01-02
HK1116779B HK1116779B (zh) 2011-05-13

Family

ID=

Also Published As

Publication number Publication date
AU2006278216A1 (en) 2007-02-15
EA200800555A1 (ru) 2008-08-29
MA29692B1 (fr) 2008-08-01
PT1912991E (pt) 2011-01-17
JP5112316B2 (ja) 2013-01-09
JP2009504591A (ja) 2009-02-05
IL189081A0 (en) 2008-08-07
CR9748A (es) 2008-05-05
EP1912992A1 (en) 2008-04-23
ATE487719T1 (de) 2010-11-15
NZ565494A (en) 2011-06-30
EP1912991A1 (en) 2008-04-23
ES2401128T3 (es) 2013-04-17
US20110257205A1 (en) 2011-10-20
MY142067A (en) 2010-08-30
MA29693B1 (fr) 2008-08-01
PE20070405A1 (es) 2007-05-06
WO2007017262A1 (en) 2007-02-15
KR20080038396A (ko) 2008-05-06
DE602006018151D1 (de) 2010-12-23
NO20081211L (no) 2008-05-08
EP2272848A1 (en) 2011-01-12
EA200800564A1 (ru) 2008-08-29
BRPI0614270A2 (pt) 2011-03-22
NO20081212L (no) 2008-05-06
CY1111757T1 (el) 2015-10-07
EP2272848B1 (en) 2012-12-26
IL189083A0 (en) 2008-08-07
HRP20100725T1 (hr) 2011-01-31
US20100168122A1 (en) 2010-07-01
US20100179128A1 (en) 2010-07-15
EA014556B1 (ru) 2010-12-30
CA2618963A1 (en) 2007-02-15
SI1912991T1 (sl) 2011-03-31
CR9749A (es) 2008-05-22
WO2007017261A1 (en) 2007-02-15
MX2008001931A (es) 2008-03-24
KR20080034993A (ko) 2008-04-22
TW200800217A (en) 2008-01-01
BRPI0615145A2 (pt) 2009-11-03
MX2008001929A (es) 2008-03-24
US8143264B2 (en) 2012-03-27
PL1912991T3 (pl) 2011-04-29
EP1912991B1 (en) 2010-11-10
DK1912991T3 (da) 2011-02-21
JP2009504592A (ja) 2009-02-05
AR055369A1 (es) 2007-08-22
AU2006278215A1 (en) 2007-02-15
CA2626723A1 (en) 2007-02-15

Similar Documents

Publication Publication Date Title
EP1912991B1 (en) Xanthine derivatives as selective hm74a agonists
US8394808B2 (en) HM74 receptor agonists:xanthine derivatives, corresponding pharmaceutical compositions, treatment methods and processes
US20100099690A1 (en) Xanthine derivatives as selective hm74a agonists
WO2006045564A1 (en) Xanthine derivatives with hm74a receptor activity
AU2005298891A1 (en) Xanthine derivatives with HM74A receptor activity
HK1116779B (zh) 作為選擇性hm74a激動劑的黃嘌呤衍生物
US20090209561A1 (en) Xanthine Derivatives with HM74A Receptor Activity
ES2354723T3 (es) Derivados de xantina como agonistas selectivos de hm74a.
HK1104530B (zh) 具有hm74a受體活性的藥物
JPH0559056A (ja) キサンチン誘導体
ZA200605785B (en) Novel compounds
RU2395511C2 (ru) Новые соединения
MXPA06009269A (en) Novel compounds
HK1146279A (zh) 作為選擇性hm74a激動劑的黃嘌呤衍生物

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20140808